What Researchers Did
Researchers randomly assigned 33 people having robotic pancreaticoduodenectomy surgery to receive hyperbaric oxygen (HBO2) before surgery or no HBO2, then compared inflammation markers, pain, surgical outcomes and long-term survival.
What They Found
In this randomized controlled trial of 33 patients having pancreaticoduodenectomy, preoperative HBO2 did not change perioperative outcomes or inflammatory markers, and overall survival was worse in the HBO2 group (p equals 0.03). Seventeen patients received HBO2 in two sessions, the evening before and the morning of surgery, and 16 did not. The abstract reports no intraoperative or postoperative differences between the groups, and no differences in ESR, IL-6, IL-10 or TGF-alpha. At postoperative day 30, the pain score was lower after HBO2 (1 versus 3, p equals 0.05). The share of positive lymph nodes was 7 percent with HBO2 and 14 percent without (p less than 0.001).
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was small, with only 33 patients, and the abstract does not explain why survival was worse after HBO2, so the survival result and the other group differences need confirmation in larger trials.